Search

Your search keyword '"Jürgenliemk-Schulz, Ina"' showing total 631 results
Start Over Author "Jürgenliemk-Schulz, Ina"
631 results on '"Jürgenliemk-Schulz, Ina"'

151. Indocyanine green versus technetium‐99m with blue dye for sentinel lymph node detection in early‐stage cervical cancer: A systematic review and meta‐analysis

Author

Baeten, Ilse G. T., primary, Hoogendam, Jacob P., additional, Jeremiasse, Bernadette, additional, Braat, Arthur J. A. T., additional, Veldhuis, Wouter B., additional, Jonges, Geertruida N., additional, Jürgenliemk‐Schulz, Ina M., additional, Gils, Carla H., additional, Zweemer, Ronald P., additional, and Gerestein, Cornelis G., additional

Published
2021
Full Text
View/download PDF

152. Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis

Author

Spampinato, Sofia, primary, Fokdal, Lars U., additional, Pötter, Richard, additional, Haie-Meder, Christine, additional, Lindegaard, Jacob C., additional, Schmid, Maximilian P., additional, Sturdza, Alina, additional, Jürgenliemk-Schulz, Ina M., additional, Mahantshetty, Umesh, additional, Segedin, Barbara, additional, Bruheim, Kjersti, additional, Hoskin, Peter, additional, Rai, Bhavana, additional, Huang, Fleur, additional, Cooper, Rachel, additional, van der Steen-Banasik, Elzbieta, additional, Van Limbergen, Erik, additional, Sundset, Marit, additional, Westerveld, Henrike, additional, Nout, Remi A., additional, Jensen, Nina B.K., additional, Kirisits, Christian, additional, Kirchheiner, Kathrin, additional, and Tanderup, Kari, additional

Published
2021
Full Text
View/download PDF

154. Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis

Author

Spampinato, Sofia, primary, Fokdal, Lars U., additional, Pötter, Richard, additional, Haie-Meder, Christine, additional, Lindegaard, Jacob C., additional, Schmid, Maximilian P., additional, Sturdza, Alina, additional, Jürgenliemk-Schulz, Ina M., additional, Mahantshetty, Umesh, additional, Segedin, Barbara, additional, Bruheim, Kjersti, additional, Hoskin, Peter, additional, Rai, Bhavana, additional, Huang, Fleur, additional, Cooper, Rachel, additional, van der Steen-Banasik, Elzbieta, additional, Van Limbergen, Erik, additional, Sundset, Marit, additional, Westerveld, Henrike, additional, Nout, Remi A., additional, Jensen, Nina B.K., additional, Kirisits, Christian, additional, Kirchheiner, Kathrin, additional, and Tanderup, Kari, additional

Published
2021
Full Text
View/download PDF

155. Response to Yuce Sari et al.

Author

Spampinato, Sofia, primary, Fokdal, Lars U., additional, Pötter, Richard, additional, Haie-Meder, Christine, additional, Lindegaard, Jacob C., additional, Schmid, Maximilian P., additional, Sturdza, Alina, additional, Jürgenliemk-Schulz, Ina M., additional, Mahantshetty, Umesh, additional, Segedin, Barbara, additional, Bruheim, Kjersti, additional, Hoskin, Peter, additional, Rai, Bhavana, additional, Huang, Fleur, additional, Cooper, Rachel, additional, van der Steen-Banasik, Elzbieta, additional, Van Limbergen, Erik, additional, Sundset, Marit, additional, Westerveld, Henrike, additional, Nout, Remi A., additional, Jensen, Nina B.K., additional, Kirisits, Christian, additional, Kirchheiner, Kathrin, additional, and Tanderup, Kari, additional

Published
2021
Full Text
View/download PDF

156. Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial

Author

Post, C, de Boer, S, Powell, M, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, Ottevanger, N, Ledermann, J, Khaw, P, D'Amico, R, Fyles, A, Baron, M, Kitchener, H, Nijman, H, Lutgens, L, Brooks, S, Jürgenliemk-Schulz, I, Feeney, A, Goss, G, Fossati, R, Ghatage, P, Leary, A, Do, V, Lissoni, A, Mccormack, M, Nout, R, Verhoeven-Adema, K, Smit, V, Putter, H, Creutzberg, C, Post, Cathalijne C B, de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Nelleke P B, Ledermann, Jonathan A, Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie Hélène, Kitchener, Henry C, Nijman, Hans W, Lutgens, Ludy C H W, Brooks, Susan, Jürgenliemk-Schulz, Ina M, Feeney, Amanda, Goss, Geraldine, Fossati, Roldano, Ghatage, Prafull, Leary, Alexandra, Do, Viet, Lissoni, Andrea A, McCormack, Mary, Nout, Remi A, Verhoeven-Adema, Karen W, Smit, Vincent T H B M, Putter, Hein, Creutzberg, Carien L, Post, C, de Boer, S, Powell, M, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, Ottevanger, N, Ledermann, J, Khaw, P, D'Amico, R, Fyles, A, Baron, M, Kitchener, H, Nijman, H, Lutgens, L, Brooks, S, Jürgenliemk-Schulz, I, Feeney, A, Goss, G, Fossati, R, Ghatage, P, Leary, A, Do, V, Lissoni, A, Mccormack, M, Nout, R, Verhoeven-Adema, K, Smit, V, Putter, H, Creutzberg, C, Post, Cathalijne C B, de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Nelleke P B, Ledermann, Jonathan A, Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie Hélène, Kitchener, Henry C, Nijman, Hans W, Lutgens, Ludy C H W, Brooks, Susan, Jürgenliemk-Schulz, Ina M, Feeney, Amanda, Goss, Geraldine, Fossati, Roldano, Ghatage, Prafull, Leary, Alexandra, Do, Viet, Lissoni, Andrea A, McCormack, Mary, Nout, Remi A, Verhoeven-Adema, Karen W, Smit, Vincent T H B M, Putter, Hein, and Creutzberg, Carien L

Abstract

Background: The survival results of the PORTEC-3 trial showed a significant improvement in both overall and failure-free survival with chemoradiotherapy versus pelvic radiotherapy alone. The present analysis was performed to compare long-term adverse events (AE) and health-related quality of life (HRQOL). Patients and methods: 660 women with high-risk endometrial cancer were randomly assigned to receive chemoradiotherapy (2 concurrent cycles of cisplatin followed by 4 cycles of carboplatin/paclitaxel) or radiotherapy alone. Toxicity was graded using CTCAE v3.0. HRQOL was measured using EORTC QLQ-C30 and CX24/OV28-subscales and compared to normative-data. An as-treated analysis was performed. Results: Median follow up was 74.6 months; 574 (87%) patients were evaluable for HRQOL. At 5 years, grade ≥2 AE were scored for 78 (38%) patients who had received chemoradiotherapy versus 46 (24%) who had received radiotherapy (p=0.008). Grade 3 AE did not differ significantly between the groups (8% vs 5%, p=0.18) at 5 years, and only one new late grade 4 toxicity had been reported. At 3 and 5 years, sensory neuropathy toxicity grade ≥2 persisted after chemoradiotherapy in 6% (vs 0% after radiotherapy, p<0.001) and more patients reported significant tingling or numbness at HRQOL (27% vs 8%, p<0.001 at 3 years; 24% vs 9%, p=0.002 at 5 years). Until 3 years, more patients who had chemoradiotherapy reported limb weakness (21% vs 5%, p<0.001) and lower physical (79 vs 87, p<0.001) and role functioning (78 vs 88, p<0.001) scores. Both treatment groups reported similar long-term global health/QOL scores, which were better than those of the normative-population. Conclusion: This study shows a long-lasting, clinically relevant, negative impact of chemoradiotherapy on toxicity and HRQOL, most importantly persistent peripheral sensory neuropathy. Physical and role functioning impairments were seen until 3 years. These long-term data are essential for patient information and

Published
2021

157. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer:Implications for shared decision making

Author

Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., Creutzberg, Carien L., Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., and Creutzberg, Carien L.

Abstract

Background: Decision making regarding adjuvant therapy for high-risk endometrial cancer is complex. The aim of this study was to determine patients' and clinicians' minimally desired survival benefit to choose chemoradiotherapy over radiotherapy alone. Moreover, influencing factors and importance of positive and negative treatment effects (i.e. attribute) were investigated. Methods: Patients with high-risk endometrial cancer treated with adjuvant pelvic radiotherapy with or without chemotherapy and multidisciplinary gynaecologic oncology clinicians completed a trade-off questionnaire based on PORTEC-3 trial data. Results: In total, 171 patients and 63 clinicians completed the questionnaire. Median minimally desired benefit to make chemoradiotherapy worthwhile was significantly higher for patients versus clinicians (10% vs 5%, p = 0.02). Both patients and clinicians rated survival benefit most important during decision making, followed by long-term symptoms. Older patients (OR 0.92 [95%CI 0.87–0.97]; p = 0.003) with comorbidity (OR 0.34 [95% CI 0.12–0.89]; p = 0.035) had lower preference for chemoradiotherapy, while patients with better numeracy skills (OR 1.2 [95%CI 1.05–1.36], p = 0.011) and chemoradiotherapy history (OR 25.0 [95%CI 8.8–91.7]; p < 0.001) had higher preference for chemoradiotherapy. Conclusions: There is a considerable difference in minimally desired survival benefit of chemoradiotherapy in high-risk endometrial cancer among and between patients and clinicians. Overall, endometrial cancer patients needed higher benefits than clinicians before preferring chemoradiotherapy.

Published
2021

158. Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva:An efficacy study

Author

van Triest, Baukelien, Rasing, Marnix, van der Velden, Jacobus, de Hullu, Joanne, Witteveen, Petronella O., Beukema, Jannet C., van der Steen-Banasik, Elsbieta, Westerveld, Henrike, Snyers, An, Peters, Max, Creutzberg, Carien L., Nout, Remi A., Lutgens, Ludy, Jürgenliemk-Schulz, Ina, van Triest, Baukelien, Rasing, Marnix, van der Velden, Jacobus, de Hullu, Joanne, Witteveen, Petronella O., Beukema, Jannet C., van der Steen-Banasik, Elsbieta, Westerveld, Henrike, Snyers, An, Peters, Max, Creutzberg, Carien L., Nout, Remi A., Lutgens, Ludy, and Jürgenliemk-Schulz, Ina

Abstract

Objective: To evaluate feasibility of chemoradiation as alternative for extensive surgery in patients with locally advanced vulvar cancer and to report on locoregional control, toxicity and survival. Methods: In a multicenter, prospective phase II trial patients with locally advanced vulvar cancer were treated with locoregional radiotherapy combined with sensitizing chemotherapy (capecitabine). Treatment feasibility, percentage locoregional control, survival and toxicity were evaluated. Results: 52 patients with mainly T2/T3 disease were treated according to the study protocol in 10 centers in the Netherlands from 2007 to 2019. Full dose radiotherapy (tumor dose of 64.8Gy) was delivered in 92% and full dose capecitabine in 69% of patients. Most prevalent acute ≥ grade 3 toxicities were regarding skin/mucosa and pain (54% and 37%). Late ≥grade 3 toxicity was reported for skin/mucosa (10%), fibrosis (4%), GI incontinence (4%) and stress fracture or osteoradionecrosis (4%). Twelve weeks after treatment, local clinical complete response (cCR) and regional control (RC) rates were 62% and 75%, respectively. After 2 years, local cCR persisted in 22 patients (42%) and RC was 58%. Thirty patients (58%) had no evidence of disease at end of follow-up (median 35 months). In 9 patients (17%) extensive surgery with stoma formation was needed. Progression free survival was 58%, 51% and 45% and overall survival was 76%, 66%, 52% at 1,2, and 5 years. Conclusions: Definitive capecitabine-based chemoradiation as alternative for extensive surgery is feasible in locally advanced vulvar cancer and results in considerable locoregional control with acceptable survival rates with manageable acute and late toxicity.

Published
2021

159. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making

Author

MS Radiotherapie, Cancer, Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., Creutzberg, Carien L., MS Radiotherapie, Cancer, Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., and Creutzberg, Carien L.

Published
2021

160. Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis

Author

MS Radiotherapie, Cancer, Spampinato, Sofia, Fokdal, Lars U., Pötter, Richard, Haie-Meder, Christine, Lindegaard, Jacob C., Schmid, Maximilian P., Sturdza, Alina, Jürgenliemk-Schulz, Ina M., Mahantshetty, Umesh, Segedin, Barbara, Bruheim, Kjersti, Hoskin, Peter, Rai, Bhavana, Huang, Fleur, Cooper, Rachel, van der Steen-Banasik, Elzbieta, Van Limbergen, Erik, Sundset, Marit, Westerveld, Henrike, Nout, Remi A., Jensen, Nina B.K., Kirisits, Christian, Kirchheiner, Kathrin, Tanderup, Kari, MS Radiotherapie, Cancer, Spampinato, Sofia, Fokdal, Lars U., Pötter, Richard, Haie-Meder, Christine, Lindegaard, Jacob C., Schmid, Maximilian P., Sturdza, Alina, Jürgenliemk-Schulz, Ina M., Mahantshetty, Umesh, Segedin, Barbara, Bruheim, Kjersti, Hoskin, Peter, Rai, Bhavana, Huang, Fleur, Cooper, Rachel, van der Steen-Banasik, Elzbieta, Van Limbergen, Erik, Sundset, Marit, Westerveld, Henrike, Nout, Remi A., Jensen, Nina B.K., Kirisits, Christian, Kirchheiner, Kathrin, and Tanderup, Kari

Published
2021

161. Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study

Author

MS Radiotherapie, Cancer, Petric, Primoz, Lindegaard, Jacob C., Sturdza, Alina, Fokdal, Lars, Kirchheiner, Kathrin, Tan, Li T., Schmid, Maximilian P., Haie-Meder, Christine, Jürgenliemk-Schulz, Ina M., van Limbergen, Erik, Hoskin, Peter, Gillham, Charles, Tharavichitkul, Ekkasit, Mahantshetty, Umesh, Villafranca, Elena, Tanderup, Kari, Kirisits, Christian, Pötter, Richard, MS Radiotherapie, Cancer, Petric, Primoz, Lindegaard, Jacob C., Sturdza, Alina, Fokdal, Lars, Kirchheiner, Kathrin, Tan, Li T., Schmid, Maximilian P., Haie-Meder, Christine, Jürgenliemk-Schulz, Ina M., van Limbergen, Erik, Hoskin, Peter, Gillham, Charles, Tharavichitkul, Ekkasit, Mahantshetty, Umesh, Villafranca, Elena, Tanderup, Kari, Kirisits, Christian, and Pötter, Richard

Published
2021

162. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

Author

MS Radiotherapie, Cancer, Post, Cathalijne C.B., de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Nelleke (P ).B., Ledermann, Jonathan A., Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie Hélène, Kitchener, Henry C., Nijman, Hans W., Lutgens, Ludy C.H.W., Brooks, Susan, Jürgenliemk-Schulz, Ina M., Feeney, Amanda, Goss, Geraldine, Fossati, Roldano, Ghatage, Prafull, Leary, Alexandra, Do, Viet, Lissoni, Andrea A., McCormack, Mary, Nout, Remi A., Verhoeven-Adema, Karen W., Smit, Vincent T.H.B.M., Putter, Hein, Creutzberg, Carien L., MS Radiotherapie, Cancer, Post, Cathalijne C.B., de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Nelleke (P ).B., Ledermann, Jonathan A., Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie Hélène, Kitchener, Henry C., Nijman, Hans W., Lutgens, Ludy C.H.W., Brooks, Susan, Jürgenliemk-Schulz, Ina M., Feeney, Amanda, Goss, Geraldine, Fossati, Roldano, Ghatage, Prafull, Leary, Alexandra, Do, Viet, Lissoni, Andrea A., McCormack, Mary, Nout, Remi A., Verhoeven-Adema, Karen W., Smit, Vincent T.H.B.M., Putter, Hein, and Creutzberg, Carien L.

Published
2021

163. Response to Yuce Sari et al.

Author

MS Radiotherapie, Cancer, Spampinato, Sofia, Fokdal, Lars U., Pötter, Richard, Haie-Meder, Christine, Lindegaard, Jacob C., Schmid, Maximilian P., Sturdza, Alina, Jürgenliemk-Schulz, Ina M., Mahantshetty, Umesh, Segedin, Barbara, Bruheim, Kjersti, Hoskin, Peter, Rai, Bhavana, Huang, Fleur, Cooper, Rachel, van der Steen-Banasik, Elzbieta, Van Limbergen, Erik, Sundset, Marit, Westerveld, Henrike, Nout, Remi A., Jensen, Nina B.K., Kirisits, Christian, Kirchheiner, Kathrin, Tanderup, Kari, MS Radiotherapie, Cancer, Spampinato, Sofia, Fokdal, Lars U., Pötter, Richard, Haie-Meder, Christine, Lindegaard, Jacob C., Schmid, Maximilian P., Sturdza, Alina, Jürgenliemk-Schulz, Ina M., Mahantshetty, Umesh, Segedin, Barbara, Bruheim, Kjersti, Hoskin, Peter, Rai, Bhavana, Huang, Fleur, Cooper, Rachel, van der Steen-Banasik, Elzbieta, Van Limbergen, Erik, Sundset, Marit, Westerveld, Henrike, Nout, Remi A., Jensen, Nina B.K., Kirisits, Christian, Kirchheiner, Kathrin, and Tanderup, Kari

Published
2021

164. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer

Author

MS Radiotherapie, Cancer, Post, Cathalijne C.B., Stelloo, Ellen, Smit, Vincent T.H.B.M., Ruano, Dina, Tops, Carli M., Vermij, Lisa, Rutten, Tessa A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., Nout, Remi A., Crosbie, Emma J., Powell, Melanie E., Mileshkin, Linda, Leary, Alexandra, Bessette, Paul, Putter, Hein, de Boer, Stephanie M., Horeweg, Nanda, Nielsen, Maartje, Wezel, Tom van, Bosse, Tjalling, Creutzberg, Carien L., MS Radiotherapie, Cancer, Post, Cathalijne C.B., Stelloo, Ellen, Smit, Vincent T.H.B.M., Ruano, Dina, Tops, Carli M., Vermij, Lisa, Rutten, Tessa A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., Nout, Remi A., Crosbie, Emma J., Powell, Melanie E., Mileshkin, Linda, Leary, Alexandra, Bessette, Paul, Putter, Hein, de Boer, Stephanie M., Horeweg, Nanda, Nielsen, Maartje, Wezel, Tom van, Bosse, Tjalling, and Creutzberg, Carien L.

Published
2021

165. Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network

Author

MS Radiotherapie, Cancer, Chopra, Supriya, Mangaj, Akshay, Sharma, Alisha, Tan, Li Tee, Sturdza, Alina, Jürgenliemk-Schulz, Ina, Han, Kathy, Huang, Fleur, Schmid, Maximilian P., Fokdal, Lars, Chargari, Cyrus, Diendorfer, Tamara, Tanderup, Kari, Potter, Richard, Nout, Remi A., MS Radiotherapie, Cancer, Chopra, Supriya, Mangaj, Akshay, Sharma, Alisha, Tan, Li Tee, Sturdza, Alina, Jürgenliemk-Schulz, Ina, Han, Kathy, Huang, Fleur, Schmid, Maximilian P., Fokdal, Lars, Chargari, Cyrus, Diendorfer, Tamara, Tanderup, Kari, Potter, Richard, and Nout, Remi A.

Published
2021

167. Online Magnetic Resonance-Guided Radiotherapy (oMRgRT) for Gynecological Cancers

Author

MS Radiotherapie, Cancer, Klinische Fysica RT, Portelance, Lorraine, Corradini, Stefanie, Erickson, Beth, Lalondrelle, Susan, Padgett, Kyle, van der Leij, Femke, van Lier, Astrid, Jürgenliemk-Schulz, Ina, MS Radiotherapie, Cancer, Klinische Fysica RT, Portelance, Lorraine, Corradini, Stefanie, Erickson, Beth, Lalondrelle, Susan, Padgett, Kyle, van der Leij, Femke, van Lier, Astrid, and Jürgenliemk-Schulz, Ina

Published
2021

168. Comparison of Library of Plans with two daily adaptive strategies for whole bladder radiotherapy

Author

Radiotherapie, Klinische Fysica RT, Cancer, MS Radiotherapie, Arts-assistenten Radiotherapie, Onderzoek Radiotherapie, den Boer, Duncan, den Hartogh, Mariska D., Kotte, Alexis N.T.J., van der Voort van Zyp, Jochem R.N., Noteboom, Juus L., Bol, Gijsbert H., Willigenburg, Thomas, Werensteijn-Honingh, Anita M., Jürgenliemk-Schulz, Ina M., van Lier, Astrid L.H.M.W., Kroon, Petra S., Radiotherapie, Klinische Fysica RT, Cancer, MS Radiotherapie, Arts-assistenten Radiotherapie, Onderzoek Radiotherapie, den Boer, Duncan, den Hartogh, Mariska D., Kotte, Alexis N.T.J., van der Voort van Zyp, Jochem R.N., Noteboom, Juus L., Bol, Gijsbert H., Willigenburg, Thomas, Werensteijn-Honingh, Anita M., Jürgenliemk-Schulz, Ina M., van Lier, Astrid L.H.M.W., and Kroon, Petra S.

Published
2021

169. Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study

Author

Onderzoek Radiotherapie, Cancer, MS Radiotherapie, MS Medische Oncologie, Arts-assistenten Radiotherapie, van Triest, Baukelien, Rasing, Marnix, van der Velden, Jacobus, de Hullu, Joanne, Witteveen, Petronella O., Beukema, Jannet C., van der Steen-Banasik, Elsbieta, Westerveld, Henrike, Snyers, An, Peters, Max, Creutzberg, Carien L., Nout, Remi A., Lutgens, Ludy, Jürgenliemk-Schulz, Ina, Onderzoek Radiotherapie, Cancer, MS Radiotherapie, MS Medische Oncologie, Arts-assistenten Radiotherapie, van Triest, Baukelien, Rasing, Marnix, van der Velden, Jacobus, de Hullu, Joanne, Witteveen, Petronella O., Beukema, Jannet C., van der Steen-Banasik, Elsbieta, Westerveld, Henrike, Snyers, An, Peters, Max, Creutzberg, Carien L., Nout, Remi A., Lutgens, Ludy, and Jürgenliemk-Schulz, Ina

Published
2021

170. Progression-free survival in patients with Ga-68-PSMA-PET-directed SBRT for lymph node oligometastases

Author

Onderzoek Radiotherapie, Cancer, Arts-assistenten Radiotherapie, Klinische Fysica RT, MS Radiotherapie, Werensteijn-Honingh, Anita M, Wevers, Anne F J, Peters, Max, Kroon, Petra S, Intven, Martijn, Eppinga, Wietse S C, Jürgenliemk-Schulz, Ina M, Onderzoek Radiotherapie, Cancer, Arts-assistenten Radiotherapie, Klinische Fysica RT, MS Radiotherapie, Werensteijn-Honingh, Anita M, Wevers, Anne F J, Peters, Max, Kroon, Petra S, Intven, Martijn, Eppinga, Wietse S C, and Jürgenliemk-Schulz, Ina M

Published
2021

171. ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology

Author

MS Radiotherapie, Cancer, Experimentele klinische fysica, Corradini, Stefanie, Alongi, Filippo, Andratschke, Nicolaus, Azria, David, Bohoudi, Omar, Boldrini, Luca, Bruynzeel, Anna, Hörner-Rieber, Juliane, Jürgenliemk-Schulz, Ina, Lagerwaard, Frank, McNair, Helen, Raaymakers, Bas, Schytte, Tine, Tree, Alison, Valentini, Vincenzo, Wilke, Lotte, Zips, Daniel, Belka, Claus, MS Radiotherapie, Cancer, Experimentele klinische fysica, Corradini, Stefanie, Alongi, Filippo, Andratschke, Nicolaus, Azria, David, Bohoudi, Omar, Boldrini, Luca, Bruynzeel, Anna, Hörner-Rieber, Juliane, Jürgenliemk-Schulz, Ina, Lagerwaard, Frank, McNair, Helen, Raaymakers, Bas, Schytte, Tine, Tree, Alison, Valentini, Vincenzo, Wilke, Lotte, Zips, Daniel, and Belka, Claus

Published
2021

172. Impact of a vacuum cushion on intrafraction motion during online adaptive MR-guided SBRT for pelvic and para-aortic lymph node oligometastases

Author

Onderzoek Radiotherapie, Cancer, MS Radiotherapie, Arts-assistenten Radiotherapie, Experimentele klinische fysica, Klinische Fysica RT, Werensteijn-Honingh, Anita M, Jürgenliemk-Schulz, Ina M, Gadellaa-Van Hooijdonk, Christa G, Sikkes, Gonda G, Vissers, Nicole G P M, Winkel, Dennis, Eppinga, Wietse S C, Intven, Martijn, Raaymakers, Bas W, Kroon, Petra S, Onderzoek Radiotherapie, Cancer, MS Radiotherapie, Arts-assistenten Radiotherapie, Experimentele klinische fysica, Klinische Fysica RT, Werensteijn-Honingh, Anita M, Jürgenliemk-Schulz, Ina M, Gadellaa-Van Hooijdonk, Christa G, Sikkes, Gonda G, Vissers, Nicole G P M, Winkel, Dennis, Eppinga, Wietse S C, Intven, Martijn, Raaymakers, Bas W, and Kroon, Petra S

Published
2021

175. Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study

Author

Petric, Primoz, primary, Lindegaard, Jacob C., additional, Sturdza, Alina, additional, Fokdal, Lars, additional, Kirchheiner, Kathrin, additional, Tan, Li T., additional, Schmid, Maximilian P., additional, Haie-Meder, Christine, additional, Jürgenliemk-Schulz, Ina M., additional, van Limbergen, Erik, additional, Hoskin, Peter, additional, Gillham, Charles, additional, Tharavichitkul, Ekkasit, additional, Mahantshetty, Umesh, additional, Villafranca, Elena, additional, Tanderup, Kari, additional, Kirisits, Christian, additional, and Pötter, Richard, additional

Published
2021
Full Text
View/download PDF

176. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study

Author

Pötter, Richard, primary, Tanderup, Kari, additional, Schmid, Maximilian Paul, additional, Jürgenliemk-Schulz, Ina, additional, Haie-Meder, Christine, additional, Fokdal, Lars Ulrik, additional, Sturdza, Alina Emiliana, additional, Hoskin, Peter, additional, Mahantshetty, Umesh, additional, Segedin, Barbara, additional, Bruheim, Kjersti, additional, Huang, Fleur, additional, Rai, Bhavana, additional, Cooper, Rachel, additional, van der Steen-Banasik, Elzbieta, additional, Van Limbergen, Erik, additional, Pieters, Bradley Rumwell, additional, Tan, Li-Tee, additional, Nout, Remi Abubakar, additional, De Leeuw, Astrid Agatha Catharina, additional, Ristl, Robin, additional, Petric, Primoz, additional, Nesvacil, Nicole, additional, Kirchheiner, Kathrin, additional, Kirisits, Christian, additional, Lindegaard, Jacob Christian, additional, Chargari, Cyrus, additional, Dumas, Isabelle, additional, Lowe, Gerry, additional, Swamidas, Jamema, additional, Hudej, Robert, additional, Paulsen Hellebust, Taran, additional, Menon, Geetha, additional, Oinam, Arun S., additional, Bownes, Peter, additional, Christiaens, Melissa, additional, De Brabandere, Marisol, additional, Janssen, Hilde, additional, Oosterveld, Bernard, additional, Koedooder, Kees, additional, Langeland Marthinsen, Anne Beate, additional, Sundset, Marit, additional, Whitney, Diane, additional, Ketelaars, Martijn, additional, Lutgens, Ludy C.H.W., additional, Reinniers, Brigitte, additional, Mora, Itxa, additional, Villafranca, Elena, additional, Antal, Gergely, additional, Hadjiev, Janaki, additional, Bachand, Francois, additional, Batchelar, Deidre, additional, Erickson, Beth, additional, Rownd, Jason, additional, Jacobson, Geraldine, additional, Kim, Yusung, additional, Anttila, Maarit, additional, Palmgren, Jan-Erik, additional, An, Jusheng, additional, Assenholt, Marianne Sanggaard, additional, Banerjee, Susovan, additional, Bentzen, Sören, additional, Berger, Thomas, additional, Dankulchai, Pittaya, additional, Diendorfer, Tamara, additional, Dilworth, Ian, additional, Dimopoulos, Johannes, additional, Dörr, Elke, additional, Ecker, Stefan, additional, Federico, Mario, additional, Fidarova, Elena, additional, Fortin, Israel, additional, Georg, Petra, additional, Gora, Joanna, additional, Hegazy, Neamat, additional, Jastaniyah, Noha, additional, Jensen, Nina Boje Kibsgaard, additional, Liederer, Thomas, additional, Majercakova, Katarina, additional, Misimovic, Dragan, additional, Motisi, Laura, additional, Najjari Jamal, Dina, additional, Nkiwane, Karen, additional, Schwartz-Vittrup, Anders, additional, Serban, Monica, additional, Smet, Stephanie, additional, Spampinato, Sofia, additional, Trnkova, Petra, additional, Valgma, Margit, additional, Westerveld, Henrike, additional, Wong, Joyce Siu Yu, additional, and Yoshida, Kenji, additional

Published
2021
Full Text
View/download PDF

177. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer

Author

Post, Cathalijne C B, primary, Stelloo, Ellen, additional, Smit, Vincent T H B M, additional, Ruano, Dina, additional, Tops, Carli M, additional, Vermij, Lisa, additional, Rutten, Tessa A, additional, Jürgenliemk-Schulz, Ina M, additional, Lutgens, Ludy C H W, additional, Jobsen, Jan J, additional, Nout, Remi A, additional, Crosbie, Emma J, additional, Powell, Melanie E, additional, Mileshkin, Linda, additional, Leary, Alexandra, additional, Bessette, Paul, additional, Putter, Hein, additional, de Boer, Stephanie M, additional, Horeweg, Nanda, additional, Nielsen, Maartje, additional, Wezel, Tom van, additional, Bosse, Tjalling, additional, and Creutzberg, Carien L, additional

Published
2021
Full Text
View/download PDF

178. Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network

Author

Chopra, Supriya, primary, Mangaj, Akshay, additional, Sharma, Alisha, additional, Tan, Li Tee, additional, Sturdza, Alina, additional, Jürgenliemk-Schulz, Ina, additional, Han, Kathy, additional, Huang, Fleur, additional, Schmid, Maximilian P., additional, Fokdal, Lars, additional, Chargari, Cyrus, additional, Diendorfer, Tamara, additional, Tanderup, Kari, additional, Potter, Richard, additional, and Nout, Remi A, additional

Published
2021
Full Text
View/download PDF

179. Target coverage and dose criteria based evaluation of the first clinical 1.5T MR-linac SBRT treatments of lymph node oligometastases compared with conventional CBCT-linac treatment

Author

Winkel, Dennis, Bol, Gijsbert H., Werensteijn-Honingh, Anita M., Intven, Martijn P.W., Eppinga, Wietse S.C., Hes, Jochem, Snoeren, Louk M.W., Sikkes, Gonda G., Gadellaa-van Hooijdonk, Christa G.M., Raaymakers, Bas W., Jürgenliemk-Schulz, Ina M., Kroon, Petra S., Winkel, Dennis, Bol, Gijsbert H., Werensteijn-Honingh, Anita M., Intven, Martijn P.W., Eppinga, Wietse S.C., Hes, Jochem, Snoeren, Louk M.W., Sikkes, Gonda G., Gadellaa-van Hooijdonk, Christa G.M., Raaymakers, Bas W., Jürgenliemk-Schulz, Ina M., and Kroon, Petra S.

Published
2020

180. Target coverage and dose criteria based evaluation of the first clinical 1.5T MR-linac SBRT treatments of lymph node oligometastases compared with conventional CBCT-linac treatment

Author

ICT RT, Experimentele klinische fysica, Klinische Fysica RT, Cancer, Onderzoek Radiotherapie, MS Radiotherapie, Arts-assistenten Radiotherapie, Winkel, Dennis, Bol, Gijsbert H., Werensteijn-Honingh, Anita M., Intven, Martijn P.W., Eppinga, Wietse S.C., Hes, Jochem, Snoeren, Louk M.W., Sikkes, Gonda G., Gadellaa-van Hooijdonk, Christa G.M., Raaymakers, Bas W., Jürgenliemk-Schulz, Ina M., Kroon, Petra S., ICT RT, Experimentele klinische fysica, Klinische Fysica RT, Cancer, Onderzoek Radiotherapie, MS Radiotherapie, Arts-assistenten Radiotherapie, Winkel, Dennis, Bol, Gijsbert H., Werensteijn-Honingh, Anita M., Intven, Martijn P.W., Eppinga, Wietse S.C., Hes, Jochem, Snoeren, Louk M.W., Sikkes, Gonda G., Gadellaa-van Hooijdonk, Christa G.M., Raaymakers, Bas W., Jürgenliemk-Schulz, Ina M., and Kroon, Petra S.

Published
2020

182. Impact of a vacuum cushion on intrafraction motion during online adaptive MR-guided SBRT for pelvic and para-aortic lymph node oligometastases

Author

Werensteijn-Honingh, Anita M., primary, Jürgenliemk-Schulz, Ina M., additional, Gadellaa-Van Hooijdonk, Christa G., additional, Sikkes, Gonda G., additional, Vissers, Nicole G.P.M., additional, Winkel, Dennis, additional, Eppinga, Wietse S.C., additional, Intven, Martijn, additional, Raaymakers, Bas W., additional, and Kroon, Petra S., additional

Published
2021
Full Text
View/download PDF

183. Dosimetric feasibility of hypofractionation for SBRT treatment of lymph node oligometastases on the 1.5T MR-linac

Author

Winkel, Dennis, primary, Werensteijn-Honingh, Anita M., additional, Eppinga, Wietse S.C., additional, Intven, Martijn P.W., additional, Hes, Jochem, additional, Snoeren, Louk M.W., additional, Visser, Sanne A., additional, Bol, Gijsbert H., additional, Raaymakers, Bas W., additional, Jürgenliemk-Schulz, Ina M., additional, and Kroon, Petra S., additional

Published
2021
Full Text
View/download PDF

184. Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer

Author

Horeweg, Nanda, primary, de Bruyn, Marco, additional, Nout, Remi A., additional, Stelloo, Ellen, additional, Kedzierska, Katarzyna, additional, León-Castillo, Alicia, additional, Plat, Annechien, additional, Mertz, Kirsten D., additional, Osse, Michelle, additional, Jürgenliemk-Schulz, Ina M., additional, Lutgens, Ludy C.H.W., additional, Jobsen, Jan J., additional, van der Steen-Banasik, Elzbieta M., additional, Smit, Vincent T., additional, Creutzberg, Carien L., additional, Bosse, Tjalling, additional, Nijman, Hans W., additional, Koelzer, Viktor H., additional, and Church, David N., additional

Published
2020
Full Text
View/download PDF

186. Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases

Author

Werensteijn-Honingh, Anita M., Kroon, Petra S., Winkel, Dennis, Aalbers, Ellart M., van Asselen, Bram, Bol, Gijsbert H., Brown, Kevin J., Eppinga, Wietse S.C., van Es, Corine A., Glitzner, Markus, de Groot-van Breugel, Eline N., Hackett, Sara L., Intven, Martijn, Kok, Jan G.M., Kontaxis, Charis, Kotte, Alexis N., Lagendijk, Jan J.W., Philippens, Mariëlle E.P., Tijssen, Rob H.N., Wolthaus, Jochem W.H., Woodings, Simon J., Raaymakers, Bas W., and Jürgenliemk-Schulz, Ina M.

Published
2019
Full Text
View/download PDF

187. Evidence-Based Dose Planning Aims and Dose Prescription in Image-Guided Brachytherapy Combined With Radiochemotherapy in Locally Advanced Cervical Cancer

Author

Tanderup, Kari, primary, Nesvacil, Nicole, additional, Kirchheiner, Kathrin, additional, Serban, Monica, additional, Spampinato, Sofia, additional, Jensen, Nina Boje Kibsgaard, additional, Schmid, Maximilian, additional, Smet, Stephanie, additional, Westerveld, Henrike, additional, Ecker, Stefan, additional, Mahantshetty, Umesh, additional, Swamidas, Jamema, additional, Chopra, Supriya, additional, Nout, Remi, additional, Tan, Li Tee, additional, Fokdal, Lars, additional, Sturdza, Alina, additional, Jürgenliemk-Schulz, Ina, additional, de Leeuw, Astrid, additional, Lindegaard, Jacob Christian, additional, Kirisits, Christian, additional, and Pötter, Richard, additional

Published
2020
Full Text
View/download PDF

188. Implementing an online radiotherapy quality assurance programme with supporting continuous medical education – report from the EMBRACE-II evaluation of cervix cancer IMRT contouring

Author

Duke, Simon L., primary, Tan, Li-Tee, additional, Jensen, Nina B.K., additional, Rumpold, Tamara, additional, De Leeuw, Astrid A.C., additional, Kirisits, Christian, additional, Lindegaard, Jacob C., additional, Tanderup, Kari, additional, Pötter, Richard C., additional, Nout, Remi A., additional, and Jürgenliemk-Schulz, Ina M., additional

Published
2020
Full Text
View/download PDF

189. Target coverage and dose criteria based evaluation of the first clinical 1.5T MR-linac SBRT treatments of lymph node oligometastases compared with conventional CBCT-linac treatment

Author

Winkel, Dennis, primary, Bol, Gijsbert H., additional, Werensteijn-Honingh, Anita M., additional, Intven, Martijn P.W., additional, Eppinga, Wietse S.C., additional, Hes, Jochem, additional, Snoeren, Louk M.W., additional, Sikkes, Gonda G., additional, Gadellaa-van Hooijdonk, Christa G.M., additional, Raaymakers, Bas W., additional, Jürgenliemk-Schulz, Ina M., additional, and Kroon, Petra S., additional

Published
2020
Full Text
View/download PDF

193. Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac : Multi-fraction treatment of pelvic lymph node oligometastases

Author

Werensteijn-Honingh, Anita M, Kroon, Petra S, Winkel, Dennis, Aalbers, Ellart M, van Asselen, Bram, Bol, Gijsbert H, Brown, Kevin J, Eppinga, Wietse S C, van Es, Corine A, Glitzner, Markus, de Groot-van Breugel, Eline N, Hackett, Sara L, Intven, Martijn, Kok, Jan G M, Kontaxis, Charis, Kotte, Alexis N, Lagendijk, Jan J W, Philippens, Mariëlle E P, Tijssen, Rob H N, Wolthaus, Jochem W H, Woodings, Simon J, Raaymakers, Bas W, Jürgenliemk-Schulz, Ina M, Werensteijn-Honingh, Anita M, Kroon, Petra S, Winkel, Dennis, Aalbers, Ellart M, van Asselen, Bram, Bol, Gijsbert H, Brown, Kevin J, Eppinga, Wietse S C, van Es, Corine A, Glitzner, Markus, de Groot-van Breugel, Eline N, Hackett, Sara L, Intven, Martijn, Kok, Jan G M, Kontaxis, Charis, Kotte, Alexis N, Lagendijk, Jan J W, Philippens, Mariëlle E P, Tijssen, Rob H N, Wolthaus, Jochem W H, Woodings, Simon J, Raaymakers, Bas W, and Jürgenliemk-Schulz, Ina M

Published
2019

194. Individual lymph nodes: 'See it and Zap it'

Author

Cancer, Onderzoek Radiotherapie, Klinische Fysica RT, MS Radiotherapie, Experimentele klinische fysica, Winkel, Dennis, Werensteijn-Honingh, Anita M, Kroon, Petra S, Eppinga, Wietse S C, Bol, Gijsbert H, Intven, Martijn P W, de Boer, Hans C J, Snoeren, Louk M W, Hes, Jochem, Raaymakers, Bas W, Jürgenliemk-Schulz, Ina M, Cancer, Onderzoek Radiotherapie, Klinische Fysica RT, MS Radiotherapie, Experimentele klinische fysica, Winkel, Dennis, Werensteijn-Honingh, Anita M, Kroon, Petra S, Eppinga, Wietse S C, Bol, Gijsbert H, Intven, Martijn P W, de Boer, Hans C J, Snoeren, Louk M W, Hes, Jochem, Raaymakers, Bas W, and Jürgenliemk-Schulz, Ina M

Published
2019

195. Evaluation of plan adaptation strategies for stereotactic radiotherapy of lymph node oligometastases using online magnetic resonance image guidance

Author

Cancer, Fysica Radiotherapie Research, Klinische Fysica RT, Arts-assistenten Radiotherapie, Onderzoek Radiotherapie, MS Radiotherapie, Experimentele klinische fysica, Winkel, Dennis, Bol, Gijsbert H., Werensteijn-Honingh, Anita M., Kiekebosch, Ilse H., van Asselen, Bram, Intven, Martijn P.W., Eppinga, Wietse S.C., Raaymakers, Bas W., Jürgenliemk-Schulz, Ina M., Kroon, Petra S., Cancer, Fysica Radiotherapie Research, Klinische Fysica RT, Arts-assistenten Radiotherapie, Onderzoek Radiotherapie, MS Radiotherapie, Experimentele klinische fysica, Winkel, Dennis, Bol, Gijsbert H., Werensteijn-Honingh, Anita M., Kiekebosch, Ilse H., van Asselen, Bram, Intven, Martijn P.W., Eppinga, Wietse S.C., Raaymakers, Bas W., Jürgenliemk-Schulz, Ina M., and Kroon, Petra S.

Published
2019

196. Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases

Author

Onderzoek Radiotherapie, Cancer, Klinische Fysica RT, MS Radiotherapie, Fysica Radiotherapie Research, Experimentele klinische fysica, Werensteijn-Honingh, Anita M, Kroon, Petra S, Winkel, Dennis, Aalbers, Ellart M, van Asselen, Bram, Bol, Gijsbert H, Brown, Kevin J, Eppinga, Wietse S C, van Es, Corine A, Glitzner, Markus, de Groot-van Breugel, Eline N, Hackett, Sara L, Intven, Martijn, Kok, Jan G M, Kontaxis, Charis, Kotte, Alexis N, Lagendijk, Jan J W, Philippens, Mariëlle E P, Tijssen, Rob H N, Wolthaus, Jochem W H, Woodings, Simon J, Raaymakers, Bas W, Jürgenliemk-Schulz, Ina M, Onderzoek Radiotherapie, Cancer, Klinische Fysica RT, MS Radiotherapie, Fysica Radiotherapie Research, Experimentele klinische fysica, Werensteijn-Honingh, Anita M, Kroon, Petra S, Winkel, Dennis, Aalbers, Ellart M, van Asselen, Bram, Bol, Gijsbert H, Brown, Kevin J, Eppinga, Wietse S C, van Es, Corine A, Glitzner, Markus, de Groot-van Breugel, Eline N, Hackett, Sara L, Intven, Martijn, Kok, Jan G M, Kontaxis, Charis, Kotte, Alexis N, Lagendijk, Jan J W, Philippens, Mariëlle E P, Tijssen, Rob H N, Wolthaus, Jochem W H, Woodings, Simon J, Raaymakers, Bas W, and Jürgenliemk-Schulz, Ina M

Published
2019

197. Adaptive radiotherapy: The Elekta Unity MR-linac concept

Author

Cancer, Fysica Radiotherapie Research, Klinische Fysica RT, Onderzoek Radiotherapie, MS Radiotherapie, Experimentele klinische fysica, Winkel, Dennis, Bol, Gijsbert H, Kroon, Petra S, van Asselen, Bram, Hackett, Sara S, Werensteijn-Honingh, Anita M, Intven, Martijn P W, Eppinga, Wietse S C, Tijssen, Rob H N, Kerkmeijer, Linda G W, de Boer, Hans C J, Mook, Stella, Meijer, Gert J, Hes, Jochem, Willemsen-Bosman, Mirjam, de Groot-van Breugel, Eline N, Jürgenliemk-Schulz, Ina M, Raaymakers, Bas W, Cancer, Fysica Radiotherapie Research, Klinische Fysica RT, Onderzoek Radiotherapie, MS Radiotherapie, Experimentele klinische fysica, Winkel, Dennis, Bol, Gijsbert H, Kroon, Petra S, van Asselen, Bram, Hackett, Sara S, Werensteijn-Honingh, Anita M, Intven, Martijn P W, Eppinga, Wietse S C, Tijssen, Rob H N, Kerkmeijer, Linda G W, de Boer, Hans C J, Mook, Stella, Meijer, Gert J, Hes, Jochem, Willemsen-Bosman, Mirjam, de Groot-van Breugel, Eline N, Jürgenliemk-Schulz, Ina M, and Raaymakers, Bas W

Published
2019

198. Cervical cancer apparent diffusion coefficient values during external beam radiotherapy

Author

Arts-assistenten Radiotherapie, Computational Imaging, Circulatory Health, Cancer, Onderzoek Radiotherapie, Klinische Fysica RT, MS Radiotherapie, de Boer, Peter, Mandija, Stefano, Werensteijn-Honingh, Anita M., van den Berg, Cornelis A.T., de Leeuw, Astrid A.C., Jürgenliemk-Schulz, Ina M., Arts-assistenten Radiotherapie, Computational Imaging, Circulatory Health, Cancer, Onderzoek Radiotherapie, Klinische Fysica RT, MS Radiotherapie, de Boer, Peter, Mandija, Stefano, Werensteijn-Honingh, Anita M., van den Berg, Cornelis A.T., de Leeuw, Astrid A.C., and Jürgenliemk-Schulz, Ina M.

Published
2019

199. Progression-free survival in patients with 68Ga-PSMA-PET-directed SBRT for lymph node oligometastases.

Author

Werensteijn-Honingh, Anita M., Wevers, Anne F. J., Peters, Max, Kroon, Petra S., Intven, Martijn, Eppinga, Wietse S. C., and Jürgenliemk-Schulz, Ina M.

Subjects
DISEASE progression, CONFIDENCE intervals, MULTIVARIATE analysis, AGE distribution, METASTASIS, TREATMENT effectiveness, CANCER patients, RISK assessment, DESCRIPTIVE statistics, CANCER fatigue, QUALITY of life, LYMPHOMAS, RADIOSURGERY, PROSTATE-specific antigen, PROSTATE tumors, LONGITUDINAL method
Abstract

Prostate cancer oligometastatic disease can be treated using stereotactic body radiotherapy (SBRT) in order to postpone start of systemic treatments such as androgen deprivation therapy (ADT). 68Ga-PSMA-PET/CT imaging allows for diagnosis of oligometastases at lower PSA values. We analysed a cohort of patients with prostate cancer lymph node oligometastases detected on PSMA-PET/CT. Ninety patients with metachronous oligometastatic prostate cancer received SBRT for 1–3 lymph node metastases diagnosed on 68Ga-PSMA-PET/CT. The primary end point was progression free survival (PFS), with disease progression defined as occurrence of either target lesion progression, new metastatic lesion or biochemical progression. Secondary outcomes were biochemical PFS (BPFS), ADT-free survival (ADT-FS), toxicity and quality of life (QoL). Baseline patient characteristics were tested for association with PFS and a preliminary risk score was created. Median follow-up was 21 months (interquartile range 10–31 months). Median PFS and BPFS were 16 and 21 months, respectively. Median ADT-FS was not reached (73% (95%-CI 62–86%) at 24 months). In multivariable analysis, younger age, higher PSA prior to SBRT and extrapelvic location were associated with shorter PFS. Grade 1 fatigue was the most predominant acute toxicity (34%). Highest grade toxicity was grade 2 for acute and late events. QoL analysis showed mild, transient increase in fatigue at 1–4 weeks after SBRT. A median PFS of 16 months was attained after SBRT for patients with PSMA-PET positive oligometastatic lymph nodes from prostate cancer. Higher pre-SBRT PSA, younger age and extrapelvic location were found to be predictors of shorter PFS. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

200. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3) : final results of an international, open-label, multicentre, randomised, phase 3 trial

Author

de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B., Ledermann, Jonathan A., Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie Helene, Jürgenliemk-Schulz, Ina M., Kitchener, Henry C., Nijman, Hans W., Wilson, Godfrey, Brooks, Susan, Carinelli, Silvestro, Provencher, Diane, Hanzen, Chantal, Lutgens, Ludy C.H.W., Smit, Vincent T.H.B.M., Singh, Naveena, Do, Viet, D'Amico, Romerai, Nout, Remi A., Feeney, Amanda, Verhoeven-Adema, Karen W., Putter, Hein, Creutzberg, Carien L., McCormack, Mary, Whitmarsh, Karen, Allerton, Rozenn, Gregory, Deborah, Symonds, Paul, Hoskin, Peter J., Adusumalli, Madhavi, Anand, Anjana, Wade, Robert, Stewart, Alexandra, Taylor, Wendy, Kruitwagen, Roy F.P.M., Hollema, Harry, Pras, Elizabeth, Snyers, An, Stalpers, Lukas, Jobsen, Jan J., Slot, Annerie, Mens, Jan Willem M., and Stam, Tanja C.

Subjects
Canada, Time Factors, Endometrial Neoplasms/mortality, Clinical Trial, Phase III, Risk Factors, Paclitaxel/administration & dosage, Journal Article, Humans, Comparative Study, Aged, Neoplasm Staging, Gynecologic Surgical Procedures/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Research Support, Non-U.S. Gov't, Australia, Carboplatin/administration & dosage, Chemoradiotherapy, Adjuvant/adverse effects, Middle Aged, Europe, Multicenter Study, Treatment Outcome, Oncology, Randomized Controlled Trial, Carcinoma, Endometrioid/mortality, Lymph Node Excision, Female, Radiotherapy, Adjuvant, Dose Fractionation, Radiation, Neoplasm Grading, Cisplatin/administration & dosage, New Zealand
Abstract

BACKGROUND: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer. METHODS: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup. Eligible women had high-risk endometrial cancer with FIGO 2009 stage I, endometrioid-type grade 3 with deep myometrial invasion or lymph-vascular space invasion (or both), endometrioid-type stage II or III, or stage I to III with serous or clear cell histology. Women were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or radiotherapy and chemotherapy (consisting of two cycles of cisplatin 50 mg/m 2 given during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m 2) using a biased-coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage of cancer, and histological type. The co-primary endpoints were overall survival and failure-free survival. We used the Kaplan-Meier method, log-rank test, and Cox regression analysis for final analysis by intention to treat and adjusted for stratification factors. The study was closed on Dec 20, 2013, after achieving complete accrual; follow-up is ongoing. PORTEC-3 is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138. RESULTS: 686 women were enrolled between Nov 23, 2006, and Dec 20, 2013. 660 eligible patients were included in the final analysis, of whom 330 were assigned to chemoradiotherapy and 330 were assigned to radiotherapy. Median follow-up was 60·2 months (IQR 48·1-73·1). 5-year overall survival was 81·8% (95% CI 77·5-86·2) with chemoradiotherapy versus 76·7% (72·1-81·6) with radiotherapy (adjusted hazard ratio [HR] 0·76, 95% CI 0·54-1·06; p=0·11); 5-year failure-free survival was 75·5% (95% CI 70·3-79·9) versus 68·6% (63·1-73·4; HR 0·71, 95% CI 0·53-0·95; p=0·022). Grade 3 or worse adverse events during treatment occurred in 198 (60%) of 330 who received chemoradiotherapy versus 41 (12%) of 330 patients who received radiotherapy (p

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results